Articles Tagged: Clinical Trial
March 5, 2015 | Category: News
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, announced today that Atlanta-based Shepherd Center, one of the nation’s top rehabilitation hospitals for spinal cord injury and brain injury, has commenced enrollment for the Phase 1/2a clinical trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical spinal cord injury (SCI).
The Phase 1/2a trial follows the successful completion of the Phase 1 trial of AST-OPC1, which met its primary endpoints of safety and feasibility when administered to five patients with neurologically complete, thoracic SCI. Continue Reading »
October 14, 2014 | Category: News
(Reuters) – The longest-running trial of stem cells derived from a human embryo found that the cells caused patients none of the problems scientists feared, such as forming tumors, and reversed partial blindness in about half the eyes receiving transplants, researchers reported on Tuesday. Continue Reading »
October 11, 2014 | Category: News
Veterinarians at Iowa State University are hoping to give 60 dogs a second chance at walking.
The university’s clinical trial for paralyzed dogs is testing a new drug that could potentially help more dogs overcome severe spinal cord injuries.
The trial is run by Dr. Nick Jeffery and Dr. Hilary Hu with ISU’s Veterinary Medical Center, and the team began recruiting for their trial in January. The trial will be using the test drug chondroitinase, an enzyme which helps to dissolve scar tissue around the dog’s injury. Continue Reading »
October 7, 2014 | Category: News
NEWARK, Calif., Oct. 7, 2014 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell based therapies for the treatment of disorders of the central nervous system, announced today that it has initiated its Pathway® Study, a Phase II proof of concept clinical trial using its proprietary HuCNS-SC® platform of human neural stem cells for the treatment of cervical spinal cord injury (SCI). Approximately 1.3 million people in the United States report being paralyzed due to an SCI, and there currently are no effective treatments available. Approximately 56% of the spinal cord injuries occur in the cervical region. Overall, approximately 13% of SCI patients have no mobility and 35% have limited mobility after the traumatic injury. Continue Reading »
September 15, 2014 | Category: News
The University of Arizona Medical Center is the site of a two-year clinical trial for a drug that could help people with acute spinal-cord injuries.
Sixty trauma centers in the U.S., Canada and Europe will test the safety and efficacy of the investigational drug SUN13837, to determine whether it can protect and regenerate spinal nerves, UA Medical Center officials say.
The study is sponsored by Asubio Pharmaceuticals, Inc. Patients will be randomly assigned to receive either a placebo or SUN13837 within 12 hours of injury and then daily for 28 days. Continue Reading »
August 25, 2014 | Category: News
Only hours after a traumatic spinal cord injury, when the life-and-death moments have passed and ongoing challenges are just coming into focus, some patients are receiving an experimental drug that may change their lives.
The investigational medication, called SUN13837, is given intravenously within 12 hours of a traumatic spinal cord injury (SCI) and then daily for 28 days. It is a fat-soluble molecule that may protect damaged neurons and even promote new nerve growth, preventing some loss of function. Continue Reading »
June 23, 2014 | Category: News
An array of techniques – some available now and others on the horizon – aim to restore movement and other functions in patients with spinal cord injuries.
A paraplegic wearing an Iron Man-like exoskeleton took the first kick of the World Cup soccer tournament during the opening ceremony in Sao Paulo, Brazil, a testament to recent advances in treating spinal cord injuries.
The robotic bodysuit took cues from the user’s brain activity to power his steps forward. It was developed by Brazilian doctor Miguel Nicolelis, who is on the faculty at Duke University, and more than 150 scientists from around the world. Continue Reading »
While human embryonic stem cells (hESCs) were originally created in 1998, it wasn’t until 2009 — over a decade later — that they were approved by the FDA for use in a clinical trial in people. It was a long wait, but the trial was quite the promising one. The clinical trial, undertaken by the Geron Corporation, was for using hESCs to treat patients with spinal cord injuries and paralysis.
Very unfortunately, the trial became stalled in late 2011, mostly due to financial concerns (but it did undoubtedly help pave the way for other hESC-based clinical trials to get FDA approval starting in 2010). Continue Reading »
April 28, 2014 | Category: News
Scaffold Designed to Facilitate Neural Growth in Spinal Cord Injury
CAMBRIDGE, Mass.–(BUSINESS WIRE)–April 28, 2014– InVivo Therapeutics Holdings Corp. (NVIV) announced today that it has begun shipment of its innovative investigational device, a degradable polymer Neuro-Spinal Scaffold for spinal cord injury (SCI) patients, for initiation of the company’s first clinical trial. InVivo has pioneered a new treatment platform utilizing a biocompatible polymer-based device that is intended to promote structural support for spinal cord regeneration while improving functional recovery and prognosis after a traumatic SCI. In preclinical studies, the Neuro-Spinal Scaffold promoted cell adhesion, neurite sprouting, the growth of remodeled spinal cord tissue containing myelinated axons, and improved motor function. Continue Reading »
April 18, 2014 | Category: News
| Spinal Cord Injury: T-1
Neuralstem, announced that the Institutional Review Board of the University of California, San Diego, School of Medicine has approved the phase I safety trial to treat chronic spinal cord injury (cSCI) with its NSI-566 stem cells. The NSI-566/cSCI phase I trial will enroll patients with thoracic spinal cord injuries (T2-T12) who have an American Spinal Injury Association (AIS) A level of impairment, between one and two years after injury. AIS A impairment, which is complete paralysis, refers to a patient with no motor or sensory function in the relevant segments at and below the injury. Continue Reading »